Allergy
- Legends of Allergy and Immunology: K. Frank AustenAbstract K. Frank Austen’s remarkable career has spanned nearly seven decades, during which time his seminal work helped to define the mechanisms of hypersensitivity reactions and its chemical constituents. His work on the biologic functions of the cysteinyl leukotrienes (cysLTs) spanned the era of classical biochemistry and physiology to the era of molecular biology. His achievements include discovering and cloning the elusive leukotriene E4 re
- Recent developments and highlights in drug hypersensitivityAbstract Drug hypersensitivity reactions (DHRs) are nowadays the third cause of allergy after rhinitis and asthma with a significant increase in prevalence in both adults and paediatric population with new drugs included as culprit. For this, DHRs represent not only a health problem but also a significant financial burden for affected individuals and health systems. Mislabelling DHRs is showing to be a relevant problem for both false label of dr
- Intranasal nanoemulsion vaccine confers long‐lasting immunomodulation and sustained unresponsiveness in a murine model of milk allergyAbstract Background Immunotherapy for food allergy requires prolonged treatment protocols and, in most cases, does not lead to durable modulation of the allergic immune response. We have demonstrated an intranasal (IN), nanoemulsion adjuvant that redirects allergen‐specific Th2 responses towards Th1 and Th17 immunity, and protects from allergen challenge after only 2‐4 monthly administrations. Here, we investigate the ability of this technolo
Allergy and Clinical Immunology
- Diagnostic Interpretation of Genetic Studies in Patients with Primary Immunodeficiency Diseases: A Working Group Report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma, and ImmunologyPublication date: Available online 27 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Ivan K. Chinn, Alice Chan, Karin Chen, Janet Chou, Morna J. Dorsey, Joud Hajjar, Artemio M. Jongco, Michael D. Keller, Lisa J. Kobrynski, Attila Kumanovics, Monica G. Lawrence, Jennifer W. Leiding, Patricia L. Lugar, Jordan S. Orange, Kiran Patel, Craig D. Platt, Jennifer M. Puck, Nikita Raje, Neil D. Romberg, Maria A. SlackAbstractGen
- 3-year follow-up after peanut food challenges: accidental reactions in allergic children and introduction failure in tolerant childrenPublication date: Available online 27 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Hannah M. Kansen, Thuy-My Le, André C. Knulst, Diana M.W. Gorissen, Cornelis K. van der Ent, Yolanda Meijer, Francine C. van Erp
- Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasonPublication date: Available online 27 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Anne K. Ellis, Charles W. Frankish, Kristen Armstrong, Lisa Steacy, Mark W. Tenn, Stephen Pawsey, Roderick P. HafnerAbstractBackgroundGrass allergen peptides are in development for the treatment of grass pollen-induced allergic rhinoconjunctivitis(ARC). A previous randomized, placebo-controlled study demonstrated grass allergen peptide
- Non-canonical β<sub>2</sub>-receptor signalingPublication date: Available online 26 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Brian Lipworth, Rory Chan, Chris RuiWen Kuo
- ReplyPublication date: Available online 26 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Blanca Camoretti-Mercado, Richard F. Lockey
- IL-33 blockade impacts mediators of persistence and exacerbation in a model of chronic airway inflammationPublication date: Available online 25 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Jeanne Allinne, George Scott, Wei Keat Lim, Dylan Birchard, Jonas S. Erjefält, Caroline Sandén, Li-Hong Ben, Amit Agrawal, Navneet Kaur, Jee Hae Kim, Vishal Kamat, Wen Fury, Tammy Huang, Neil Stahl, George D. Yancopoulos, Andrew J. Murphy, Matthew A. Sleeman, Jamie M. OrengoAbstractBackgroundSevere inflammatory airway diseases are asso
- ReplyPublication date: Available online 25 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Sabine Flicker, Musa Khaitov, Rudolf Valenta
- Increased thrombin activatable fibrinolysis inhibitor (TAFI) in chronic rhinosinusitis with nasal polypsPublication date: Available online 25 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Yoshimasa Imoto, Atsushi Kato, Tetsuji Takabayashi, Whitney Stevens, James E. Norton, Lydia A. Suh, Roderick G. Carter, Ava R. Weibman, Kathryn E. Hulse, Kathleen E. Harris, Anju T. Peters, Leslie C. Grammer, Bruce K. Tan, Kevin Welch, Stephanie Shintani-Smith, David B. Conley, Robert C. Kern, Shigeharu Fujieda, Robert P. SchleimerAbst
- Does maternal IgG protect infants from allergen-specific IgE sensitization?Publication date: Available online 25 September 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Rob C. Aalberse, Ulrike Gehring, Marjan Tewis, Theo Rispens
Annals of Allergy, Asthma & Immunology
- Allergy in frequent travelers: the alpha-gal story and the first UK case series.Galactose-α-(1,3)-galactose(alpha-gal) is found in most non-primate mammalian cell membranes1. Humans, apes and Old World monkeys lack alpha-1,3 galactosyltransferase required for the synthesis of this carbohydrate2. It is therefore highly immunogenic to humans and implicated in alpha-gal syndrome/allergy - the first non-infectious tick-borne disease in humans3. Alpha-gal moiety has been found in tick salivary proteins and primary IgE sensitisati
- “ Idiopathic anaphylaxis successfully treated with omalizumab”Idiopathic anaphylaxis (IA) is a rare condition that can be lethal.1Prophylactic regimens for frequent attacks are not yet standardized. These may include long-term systemic corticosteroids, high dose antihistamines, and mast cell stabilizers. Despite these regimens, patients may become corticosteroid dependent (20%) and develop potential side effects 2. Omalizumab is a monoclonal anti-IgE antibody which is indicated in uncontrolled moderate to s
- Geospatial Distribution and Characteristics of Eosinophilic Gastrointestinal Disorder Clinics in the United StatesEosinophilic gastrointestinal disorders (EGIDs) are a group of rare disorders characterized by eosinophilic inflammation affecting parts of the gastrointestinal tract, with eosinophilic esophagitis (EoE) being the most well-studied EGID.1 In the United States (US), approximately 57 of 100,000 individuals are affected by EoE and about 18 of 100,000 individuals are affected by non-EoE EGIDs.2, 3 Complex interactions between EGIDs and allergic comor
- A novel variant in SERPING1 gene causing angioedema in a patient with C1q low levelsAngioedema consists in a localized swelling of deep dermis, subcutaneous or submucosal tissues due to an extravasation of fluid into the interstitium. It could be divided into histaminergic angioedema, typically accompanied by pruritus and/or urticaria, and bradykinin angioedema. In bradykinin-mediated endotype, angioedema results from the generation of bradykinin, triggering an increase of vascular permeability. These forms are not associated wi
- Allergy in frequent travelers: the alpha-gal story and the first UK case series.Publication date: Available online 28 September 2019Source: Annals of Allergy, Asthma & ImmunologyAuthor(s): Verah Harper, Annette Wagner, Pawel Sowa, Krzysztof Rutkowski
- A novel variant in SERPING1 gene causing angioedema in a patient with C1q low levelsPublication date: Available online 27 September 2019Source: Annals of Allergy, Asthma & ImmunologyAuthor(s): María-Alicia Calvo-Ferrer, Samuel Martín-Rodríguez, Nerea Ortega-Unanue, Ángel-Javier Blasco-Sarramián, Iván Bernardo-González
- Geospatial Distribution and Characteristics of Eosinophilic Gastrointestinal Disorder Clinics in the United StatesPublication date: Available online 27 September 2019Source: Annals of Allergy, Asthma & ImmunologyAuthor(s): Christine RF. Rukasin, Jonathan A. Hemler, Evan S. Dellon, Stacy Curry-Johnson, Girish Hiremath
- “ Idiopathic anaphylaxis successfully treated with omalizumab”Publication date: Available online 27 September 2019Source: Annals of Allergy, Asthma & ImmunologyAuthor(s): Maria C. Sanchez-Valenzuela, Juan C. Garcia-Saucedo, Gabriel Motoa, Ismael Carrilo-Martin, Alexei Gonzalez-Estrada
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου